Ocular Graft-Versus-Host Disease

Balasubramaniam, Saranya C.; Raja, Harish; Nau, Cherie B; Shen, Joanne F; Schornack, Muriel

doi:10.1097/icl.0000000000000150

Cited by 23 publications

(21 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 oGVHD patients usually suffer from refractory severe DED that compromise their quality of life. 3 The physiopathology of oGVHD is complex including lacrimal gland infiltration by fibroblasts and lymphocytes-T leading to severe aqueous deficiency and fibrosis. 4 The clinical characteristics of oGVHD are similar to DED derived from an autoimmune systemic disease such as Sjögren syndrome.…”

Section: Introductionmentioning

confidence: 99%

Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases

Sánchez-Ávila

Merayo‐Lloves

Muruzábal

et al. 2018

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy and safety of plasma rich in growth factors eye drops for the treatment of corneal and ocular surface disorders in patients with graft versus host disease. Methods: This retrospective and longitudinal study included graft versus host disease patients with ocular disorders. The resolution of corneal ulcers (area and density staining) was evaluated as primary outcome. Best corrected visual acuity, intraocular pressure, tear film breakup time, Schirmer test, ocular surface disease index, and visual analog score were evaluated as secondary outcomes. All variables were analyzed before and after plasma rich in growth factors treatment. The safety of plasma rich in growth factors treatment was also assessed. Results: Twelve patients (23 eyes) with ocular graft versus host disease were evaluated. Statistically significant improvement in the area (75.7%) and density (73.3%) of the corneal staining, in best corrected visual acuity (74.7%), in ocular surface disease index scale (75.4%), visual analog score frequency (81.4%) and visual analog score severity (81.9%), and an increase of 3.8 s in tear film breakup time and 6 mm in Schirmer test was observed after plasma rich in growth factors treatment (p < 0.001). Some potential modifiers of the therapeutic effect were identified. All patients achieved corneal stability without perforation risk. No adverse events associated with the plasma rich in growth factors were observed. Conclusion: Immunosafe plasma rich in growth factors eye drops for the treatment of patients with ocular graft versus host disease could be safe and effective, showing a high rate of corneal ulcer resolution and dry eye disease control. Plasma rich in growth factors eye drops may help to maintain corneal stability and prevent it against higher ocular complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases

Sánchez-Ávila

Merayo‐Lloves

Muruzábal

et al. 2018

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…after either bone marrow transplantation and haematopoietic stem cell transplantation, has been reported to be between 40-60 %, with a higher incidence after bone marrow transplantation (~60 %) [217][218][219].…”

Section: Chronic Graft Versus Host Diseasementioning

confidence: 99%

BCLA CLEAR – Medical use of contact lenses

Jacobs

Carrasquillo²,

Cottrell

et al. 2021

Contact Lens and Anterior Eye

View full text Add to dashboard Cite

The medical use of contact lenses is a solution for many complex ocular conditions, including high refractive error, irregular astigmatism, primary and secondary corneal ectasia, disfiguring disease, and ocular surface disease. The development of highly oxygen permeable soft and rigid materials has extended the suitability of contact lenses for such applications. There is consistent evidence that bandage soft contact lenses, particularly silicone hydrogel lenses, improve epithelial healing and reduce pain in persistent epithelial defects, after trauma or surgery, and in corneal dystrophies. Drug delivery applications of contact lens hold promise for improving topical therapy. Modern scleral lens practice has achieved great success for both visual rehabilitation and therapeutic applications, including those requiring retention of a tear reservoir or protection from an adverse environment. This report offers a practical and relevant summary of the current evidence for the medical use of contact lenses for all eye care professionals including optometrists, ophthalmologists, opticians, and orthoptists. Topics covered include indications for use in both acute and chronic conditions, lens selection, patient selection, wear and care regimens, and recommended aftercare schedules. Prevention, presentation, and management of complications of medical use are reviewed.

show abstract

“…First‐line therapy for dry eye management is application of the artificial tears; however in more symptomatic patients, topical CS and cyclosporine (or tacrolimus which requires compounding) can be used to reduce the inflammation (Munir & Aylward, ; Rapoport et al, ). Topical pilocarpine is as an effective cholinergic agent to stimulate tear production (Balasubramaniam, Raja, Nau, Shen, & Schornack, ). Placement of punctal plugs, thereby blocking the tear duct to maintain moisture of the eyes, can be effective (Sabti, Halter, Braun Frankl, & Goldblum, ).…”

Section: Management Of Cgvhdmentioning

confidence: 99%

Chronic graft‐versus‐host disease: Current management paradigm and future perspectives

et al. 2018

View full text Add to dashboard Cite

Chronic GVHD is a serious disease which may be active for years, or even decades, requiring potentially years of immunosuppressive therapies and placing patients at risk for a number of late complications. While the oral cavity has long been recognized to be a prominent target of GVHD, and in particular, chronic GVHD, it must be recognized and appreciated that it is a complex systemic disease with a wide spectrum of clinical manifestations.

show abstract

Ocular Graft-Versus-Host Disease

Cited by 23 publications

References 53 publications

Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases

Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases

BCLA CLEAR – Medical use of contact lenses

Chronic graft‐versus‐host disease: Current management paradigm and future perspectives

Contact Info

Product

Resources

About